Immunocore Holdings (Immunocore Holdings) Change In Receivables : $-25.9 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Change In Receivables?

Immunocore Holdings's change in receivables for the quarter that ended in Mar. 2024 was $-7.9 Mil. It means Immunocore Holdings's Accounts Receivable increased by $7.9 Mil from Dec. 2023 to Mar. 2024 .

Immunocore Holdings's change in receivables for the fiscal year that ended in Dec. 2023 was $-22.6 Mil. It means Immunocore Holdings's Accounts Receivable increased by $22.6 Mil from Dec. 2022 to Dec. 2023 .

Immunocore Holdings's Accounts Receivable for the quarter that ended in Mar. 2024 was $73.4 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Immunocore Holdings's Days Sales Outstanding for the three months ended in Mar. 2024 was 74.75.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Immunocore Holdings's liquidation value for the three months ended in Mar. 2024 was $309.7 Mil.

Immunocore Holdings Change In Receivables Historical Data

The historical data trend for Immunocore Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Change In Receivables Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

2.40

-0.72

-6.47

-31.99

-22.62

Immunocore Holdings Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-4.34	0.02	-1.65	-16.43	-7.88

Immunocore Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.9 Mil.

Immunocore Holdings (NAS:IMCR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Immunocore Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	73.385	/	89.583	*	91
=	74.75

2. In Ben Graham's calculation of liquidation value, Immunocore Holdings's accounts receivable are only considered to be worth 75% of book value:

Immunocore Holdings's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1058.222	-	806.166	+	0.75 * 73.385	+	0.5 * 5.295
=	309.7

Immunocore Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings (Immunocore Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

6YG:Germany 6YG:Germany

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.